101
Participants
Start Date
December 16, 2020
Primary Completion Date
June 21, 2023
Study Completion Date
June 21, 2023
Durvalumab
Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
Cisplatin
Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
Etoposide
Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
Carboplatin
Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
Research Site, Badajoz
Research Site, Barcelona
Research Site, Castellon
Research Site, Córdoba
Research Site, A Coruña
Research Site, Santiago de Compostela
Research Site, Granada
Research Site, San Sebastián
Research Site, Jaén
Research Site, León
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Majadahonda
Research Site, Málaga
Research Site, Murcia
Research Site, Ourense
Research Site, Oviedo
Research Site, San Cristóbal de La Laguna
Research Site, Santander
Research Site, Reus,Tarragona
Research Site, Toledo
Research Site, Valencia
Research Site, Valladolid
Research Site, Galdakao
Research Site, Zaragoza
Research Site, Alicante
Research Site, Badalona
Research Site, Barcelona
Research Site, Barcelona
Research Site, Barcelona
Research Site, Mataró
Research Site, Palma
Lead Sponsor
AstraZeneca
INDUSTRY